Compared to Estimates, International Flavors (IFF) Q1 Earnings: A Look at Key Metrics

Core Insights - International Flavors (IFF) reported revenue of $2.84 billion for the quarter ended March 2025, reflecting a year-over-year decline of 1.9% [1] - The company's EPS was $1.20, an increase from $1.13 in the same quarter last year, surpassing the consensus estimate of $1.12 by 7.14% [1] Revenue Performance - Health & Biosciences net sales reached $540 million, exceeding the average estimate of $532.05 million, marking a year-over-year increase of 1.7% [4] - Scent segment net sales were $614 million, slightly above the estimated $609.74 million, but down 4.8% compared to the previous year [4] - Pharma Solutions net sales amounted to $266 million, significantly surpassing the estimated $233.97 million, with a year-over-year growth of 17.2% [4] EBITDA Analysis - Adjusted Operating EBITDA for Health & Biosciences was $138 million, below the average estimate of $159.94 million [4] - Pharma Solutions reported an Adjusted Operating EBITDA of $54 million, exceeding the estimated $45.50 million [4] - Scent's Adjusted Operating EBITDA was $144 million, slightly above the average estimate of $140.59 million [4] Stock Performance - IFF shares have returned +11.9% over the past month, outperforming the Zacks S&P 500 composite's +11.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]